Boehringer wins accelerated approval for first-line use of lung cancer drug

Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated

AI Summary: Regulators accelerated approval of Boehringer Ingelheim’s lung cancer therapy for first‑line use, leveraging a priority review mechanism that sped the timeline. The label expansion places the drug into earlier treatment settings, reflecting promising data and the efficiency (and occasional controversy) of voucher‑assisted regulatory pathways.

Novartis to build $23B radioligand therapy site

Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…

AI Summary: Novartis announced plans to construct a 46,000‑square‑foot radioligand therapy manufacturing facility in Denton, Texas, part of a broader $23 billion U.S. expansion. The site aims to boost domestic production capacity for targeted radiopharmaceuticals, signaling Big Pharma’s bet that radioligand therapies will be a growth engine — and a lovely way to justify large real estate footprints.

Patient dies in MacroGenics' cancer study, FDA puts trial on hold

Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...

AI Summary: Regulators have imposed a partial hold on a Phase 2 gynecologic cancer trial after multiple serious adverse events, including one patient death and additional safety incidents. The pause mandates review of trial protocols and safety monitoring before enrollment can resume, highlighting the inherent risks when experimental therapies meet human biology.

Cancer blood test fails to catch disease earlier in major study

medicalxpress - A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it.

AI Summary: A large trial evaluating GRAIL’s multi‑cancer blood screening test failed to meet its primary goal of earlier cancer detection. The disappointing result casts doubt on the test’s clinical utility for population screening, sparks debate over marketing and clinical use, and prompts calls for clearer evidence before widespread adoption.

More Research, Less Cancer: £250m raised to transform the future of cancer research

Charlotte Mathé / cancerresearchuk - We’ve reached an incredible moment - £250m raised for our More Research, Less Cancer campaign. This milestone brings us more than halfway to our £400m goal and accelerates our mission to prevent, detect and treat cancer earlier and more effectively. The p…

AI Summary: The More Research Less Cancer campaign has reached a £250 million fundraising milestone to accelerate cancer research, support translational projects, and expand patient-focused initiatives. Donor momentum will underwrite discovery science and clinical translation, giving researchers more runway to turn promising lab findings into treatments patients might actually see.

Gilead to acquire cell therapy manufacturer for $7.8B

Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…

AI Summary: Gilead Sciences agreed to acquire Arcellx for $7.8 billion to secure manufacturing and commercialization of a leading multiple myeloma CAR‑T candidate. The deal folds Arcellx’s anito‑cel program into Gilead’s oncology portfolio, accelerating regulatory filings and scale‑up plans — because buying your way into cutting‑edge cell therapy apparently never goes out of style.

Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin

esmo - Findings from the KEYNOTE-905/EV-303 study

AI Summary: KEYNOTE‑905/EV‑303 results show perioperative enfortumab vedotin combined with pembrolizumab significantly improved event‑free survival, overall survival and pathological complete response in muscle‑invasive bladder cancer patients ineligible for cisplatin. The findings could shift neoadjuvant strategies for this high‑risk group and spur guideline updates and broader adoption in practice.

Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC

oncodaily - International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn: “2026 TTLC Symposia Event Data and Decisions in Advanced NSCLC The treatment landscape for advanced NSCLC is evolving […]

AI Summary: TTLC 2026 brought together lung cancer experts to present symposia on advanced NSCLC topics — from RAS inhibition to mechanisms of EGFR resistance — and unveiled new clinical data. The meeting, including LungCancerRx LIVE Season 2 sessions, fostered debate, rapid data exchange and collaborations likely to steer upcoming trials and treatment approaches.

Mysterious Virus Hiding Inside Common Gut Bacterium Linked to Colorectal Cancer

discovermagazine - A previously unknown virus may be the key to assessing the risk of colorectal cancer and improving diagnosis.

AI Summary: Scientists have identified a novel virus residing within a common gut bacterium that appears associated with colorectal cancer, offering a potential new biomarker for risk and diagnosis. Early work suggests this viral–microbe interaction could reshape screening strategies if subsequent studies confirm causation and clinical utility.

Grail’s Galleri Blood Test Falls Short in Large Cancer-Screening Study, Shares Sink 50%

Frank Vinluan / medcitynews - Despite missing statistical significance, Grail said the observation of trending improvement suggests potential for better results with more time, so the company is extending follow up by up to a year. More detailed trial results will be submitted for pre…

AI Summary: Grail’s multi‑cancer Galleri blood screen failed to meet the primary endpoint in a large UK trial, undermining claims of near-term population screening utility and prompting a sharp market reaction. Researchers noted signals that merit further study, but the study outcome raises fresh doubts about broad clinical deployment and reimbursement prospects.

Your Cat May Share the Same Cancer Genes as You, and Offer Clues for Treatment

discovermagazine - Learn how cats and humans can share key cancer mutations — and why those similarities could guide future treatment research.

AI Summary: A comparative genomics study finds the household cat shares key cancer mutations with humans across several tumor types, offering a practical animal model for understanding tumor biology and testing therapies. Researchers suggest these feline-human parallels could accelerate translational oncology for both species, turning a once-dismissed pet anecdote into useful science.

New FDA-Approved Device Uses Electric Fields to Treat Pancreatic Cancer

discovermagazine - Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.

AI Summary: The FDA approved a wearable device that delivers alternating electric fields to disrupt pancreatic tumor growth, letting patients remain ambulatory while receiving treatment. Clinicians hail the noninvasive approach as a new adjunct to standard care, aiming to slow progression in a cancer that’s notoriously hard to treat — and yes, it literally plugs into hope.